Back

Effect of SGLT-1/2 inhibition on mitochondrial dysfunction in left atrial remodeling during HFpEF.

28 August 2020 (08:00 - 18:00)
Organised by:
Congress Presentation Part of: Chronic Heart Failure ePosters Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Premium Access ESC Congress 2020

About the speaker

Photo
Mr David Bode

Charite University Hospital, Berlin (Germany)

274 More presentations in this session

Presentation thumbnail
Increased myocardial fat supply improves cardiac energetics and function in heart failure
Doctor W. Watson (Cambridge, GB)
Abstract Slides
Presentation thumbnail
Cardiac aging is regulated by autophagic disorder mediated by chronic inflammation via the Rubicon/NOX4 pathway.
Doctor T. Kamihara (Obu, JP)
Abstract Slides
Presentation thumbnail
Participants with diabetes have less augmentation in cardiac function and energetics in response to increased supply of fatty acid
Doctor P. Green (Hobart, AU)
Abstract Slides
Presentation thumbnail
Impaired high-density lipoprotein function in patients with heart failure
Ms L. Emmens (Groningen, NL)
Abstract Slides
Presentation thumbnail
The comparison of clinical significance between atrial and ventricular structural remodeling in patients with heart failure with preserved ejection fraction - insights from PURSUIT-HFpEF registry
Doctor M. Okada (Osaka, JP)
Abstract Slides

Access the full session

Session thumbnail
Chronic Heart Failure ePosters

The Event

Event poster

ESC Congress 2020

28 August 2020 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Effect of SGLT2i empagliflozin on left ventricular and mitochondrial function in a porcine model of anthracycline-induced cardiotoxicity
20 May 2023
thumbnail
Congress Presentation
The role of mitochondrial dysfunction in atrial fibrillation
31 August 2024
thumbnail
Congress Presentation
Metabolic syndrome contributes to the pulmonary arterial dysfunction in pulmonary hypertension in heart failure with preserved ejection fraction
31 August 2020
thumbnail
Congress Presentation
Impact on atrial remodeling of dapagliflozin in patients with heart failure: MODA study. rational and design.
20 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources